Regis Healthcare shares down 2% as CEO resigns

Dr Mellors will step down as CEO after more than six years in the role.

| More on:

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Key points
  • Regis Healthcare CEO has resigned and is pursuing an opportunity outside the aged care sector.
  • Despite being up 20% for the year, Regis shares have been on a wild ride, climbing 53% to $9.22 before a September funding update triggered a 35% sell-off.
  • With a CEO search underway and government funding reforms still bedding down, the market appears cautious, focused on execution, labour cost control, and delivery of FY26 earnings.

Shares in Regis Healthcare Ltd (ASX: REG) are down 2% after the aged care operator announced the resignation of Chief Executive Officer Dr Linda Mellors.

In an ASX release, Regis confirmed that Dr Mellors will step down after more than six years in the role, having decided to pursue an opportunity outside the aged care sector. She will remain in her position during a six-month notice period while the board conducts an executive search and manages a transition of responsibilities.

While leadership changes can prompt short-term uncertainty, today's share price reaction also needs to be viewed in the context of a volatile year for Regis investors.

A man packs up a box of belongings at his desk as he prepares to leave the office.

Image source: Getty Images

A strong year with a sharp reversal

On the surface, Regis shares are still up about 20% year to date, having started the year around $6. However, that headline gain masks a much bumpier journey.

Earlier in 2025, optimism around Regis shares, powered by sector reform and operational improvements, drove the Regis share price up as much as 53%, peaking at $9.22. That rally came to an abrupt end on 22 September, when the company released a funding update outlining the impact of changes to government aged care funding models.

At the time, Regis revealed that increases under the Australian National Aged Care Classification (AN-ACC) framework would fall well short of expectations, largely due to reweighting across resident classifications. The announcement triggered a sharp reassessment by the market, with the share price falling around 35% back to $6, effectively wiping out the year's gains.

Why today's news matters

Against that backdrop, the resignation of the CEO introduces another layer of uncertainty. Dr Mellors led Regis through major industry upheavals, including the Royal Commission into Aged Care, the COVID-19 pandemic, and the rollout of the new Aged Care Act. The board acknowledged her role in stabilising and transforming the business, noting that Regis remains in a strong financial and operational position.

However, investors appear cautious about leadership change at a time when the company is still adjusting to funding pressures and wage cost increases across the sector.

What's next for Regis?

An executive search is now underway, and the company has emphasised continuity during the transition period. For shareholders, attention will likely return to how Regis navigates government funding reforms, manages labour costs, and delivers on its FY26 earnings outlook.

For now, the market reaction suggests investors are taking a "wait and see" approach, wary after September's funding shock, but still recognising the longer-term recovery story remains intact.

Motley Fool contributor Kevin Gandiya has no positions in any of the stocks mentioned. The Motley Fool Australia's parent company Motley Fool Holdings Inc. has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

More on Healthcare Shares

Modern accountant woman in a light business suit in modern green office with documents and laptop.
Healthcare Shares

How much would $10,000 become if CSL shares returned to their record high?

After a sharp decline, CSL is in a new phase. The question is what happens next.

Read more »

A man clenches his fists with glee having seen the share price go up on the computer screen in front of him.
Healthcare Shares

Why this ASX biotech stock just rocketed 89% today

Immutep shares rocket after a fresh FDA win

Read more »

Two lab workers fist pump each other.
Healthcare Shares

Orthocell shares soar 22% on landmark US breakthrough

The company has been given approval to sell Remplir in more than 220 hospitals in the US.

Read more »

Shot of a scientist using a computer while conducting research in a laboratory.
Healthcare Shares

This ASX biotech stock just jumped again as its lead drug trial moves ahead

The latest trial milestone sends this ASX biotech stock higher today.

Read more »

Scientist looking at a laptop thinking about the share price performance.
Healthcare Shares

Why are Telix shares sinking 7.5% today?

Let's see what this healthcare stock has announced today.

Read more »

A smiling businessman sits at a desk with bags of mony, indicating a share price rise after funding has been approved
Healthcare Shares

Telix Pharmaceuticals upsizes convertible bonds to US$600 million

Telix Pharmaceuticals has upsized its convertible bond issue to US$600 million, enhancing financial flexibility and repurchasing existing bonds.

Read more »

Three people in a corporate office pour over a tablet, ready to invest.
Healthcare Shares

Telix Pharmaceuticals Investor Presentation: 56% FY25 revenue growth, pipeline advances

Telix Pharmaceuticals books 56% higher FY25 revenue, advances clinical pipeline, and issues upbeat FY26 guidance.

Read more »

A woman looks unimpressed on a blue background.
Healthcare Shares

What on earth's going on with CSL shares?

CSL’s growth slowed, and its premium valuation reset hard.

Read more »